New trial
Phase 2/3 Trial of L-Annamycin Topoisomerase II Inhibitor in AML Remission Induction
- Trial ID
- NCT06788756 on ClinicalTrials.gov
- Cancer type
- AML: Acute Myeloid Leukemia
- Stage of research
- Exploratory
- Location
- 3 Locations
- Published in
- New in Oncology - Aug 1, 2025
This pivotal adaptive study evaluates L-Annamycin (a liposomal topoisomerase II inhibitor) plus Cytarabine versus placebo with Cytarabine for remission induction in adults with refractory/relapsed AML. The randomized, double-blind trial features an initial dose-finding phase followed by an expansion phase to determine the optimal regimen, with oversight by Moleculin Biotech, Inc.
More in acute myeloid leukemia and MDS
-
Trial result · Oct 22, 2026 · NCT03672539
CPX-351 (liposomal daunorubicin/cytarabine) + CD33-targeted gemtuzumab ozogamicin delivers 19% CRc in heavily pretreated R/R AML -
New trial · Oct 15, 2026 · NCT07809906
Phase 1 ORM-1153 CD123-directed degrader-antibody conjugate delivers a GSPT1-degrading payload in hematologic malignancies -
Trial result · Sep 17, 2026 · NCT02159495
CD123 CAR-T Delivers ~27% CR/CRi in Post-alloHCT AML With Manageable CRS/Neurotoxicity -
New trial · Sep 10, 2026 · NCT07581002
Phase 2/3 Pivekimab sunirine CD123-targeted ADC (IGN payload) + venetoclax/azacitidine in AML -
New trial · Sep 10, 2026 · NCT07780565
Phase 1b monzosertib CDC7 kinase inhibitor tests azole–drug interaction dosing in AML/MDS